Targovax ASA logo

TRVX - Targovax ASA News Story

NOK6.33 -0.0  -0.2%

Last Trade - 11:51am

Sector
Healthcare
Size
Micro Cap
Market Cap £41.6m
Enterprise Value £35.8m
Revenue £221k
Position in Universe 1021st / 1792

BRIEF-Targovax Announces Encouraging Results From Part 1 Of The Oncos-102 And Keytruda Combination Trial In Anti-Pd1 Refractory Melanoma

Mon 8th July, 2019 5:32pm
July 8 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX ANNOUNCES ENCOURAGING RESULTS FROM PART 1 OF THE
ONCOS-102 AND KEYTRUDA COMBINATION TRIAL IN ANTI-PD1 REFRACTORY
MELANOMA
    * PART 1 SAFETY DATA SHOWS THAT SEQUENTIAL ONCOS-102 AND
KEYTRUDA
TREATMENT REGIMEN IS WELL TOLERATED
    * INNATE AND ADAPTIVE IMMUNE ACTIVATION OBSERVED IN NINE OUT
OF
NINE PATIENTS
    * TARGOVAX - PART 2 TRIAL ENROLLING PATIENTS WHERE SAFETY,
EFFICACY OF MORE INTENSIVE TREATMENT REGIMEN OF 12 ONCOS-102
INJECTIONS WILL BE EVALUATED

Source text for Eikon:  ID:nWkr84rDdg 
Further company coverage:  TRVX.OL 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.